Drugs / Actovegin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03469349 | May 2018 → May 2019 | peripheral arterial occlusive disease 1 | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00483730 | Dec 2006 → May 2008 | diabetic polyneuropathy | Nycomed | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03543917 Background | Aug 2017 → Aug 2018 | stroke disorder | Fundatia Bio-Forum | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01582854 Comparator | Jun 2012 → Nov 2014 | cognitive disorder | Takeda | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Actovegin | “Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours” NCT03543917 ↗ |
| Modality | Protein / enzyme biologic | “Actovegin (a deproteinized hemoderivative of calf blood, 2000 mg/d for ≤20 intravenous infusions followed by 1200 mg/d orally)” PMID 28432265 ↗ May 2017 |
| Route | Intravenous | “250 ml i.v. infusions once daily for 20 days followed by oral treatment 600 mg × 3 daily for 140 days.” NCT00483730 ↗ |
| Route | Oral | “250 ml i.v. infusions once daily for 20 days followed by oral treatment 600 mg × 3 daily for 140 days.” NCT00483730 ↗ |